- Nova MSC signs MoU with AMO and RHAZES that
will enable the deployment of its EyRIS' AI-Deep Learning Technology,
SELENA+ to more than 1,000 AMO members via RHAZES Telehealth
- SELENA+ is capable of detecting up to 3
retinal diseases, principally diabetic retinopathy, glaucoma suspect
and age-related macular degeneration
- EyRIS SELENA+ will also become a gamechanger
in first stage diagnostic with the addition of a new algorithm to detect
chronic kidney disease (CKD)
- EyRIS has inked a Research Collaboration
Agreement with a specialty centre under the National Healthcare Group
(NHG) to develop a new proprietary AI that detects melanoma using a mobile
MALAYSIA - Media OutReach - 21 February 2022 - Nova MSC
Berhad ("Nova MSC" or
"the Company"), which is the exclusive distributor of EyRIS Pte Ltd's ("EyRIS")
products, has signed a Memorandum of Understanding ("MoU") with the Association
of Malaysian Optometrists ("AMO") and Rhazes Consultancy Services Sdn
Bhd ("RHAZES"), a tele-pharmacy platform provider, to bring its AI Deep
Learning Technology, SELENA+ to mainstream adoption in Malaysia.
Under the collaboration, EyRIS' AI deep
learning technology, SELENA+, will be deployed to AMO's more than 1,000
members across Malaysia via RHAZES Telehealth. RHAZES Telehealth is
Malaysia's first knowledge-based telehealth service provider through its brand
EyRIS is 42% owned by novaHEALTH Pte Ltd, which in turn is
wholly-owned by Nova MSC.
Nova MSC's General Manager, Mr
Nazerollnizam Kasim, said, "We are
optimistic that the collaboration with both AMO and RHAZES will drive forward
the adoption of SELENA+ in Malaysia. During the pandemic, we have seen a rise
in telehealth and how it has gradually moved towards mainstream adoption."
According to En. Ahmad Fadhullah Fuzai, President of AMO, "The deployment of
SELENA+ to AMO's member practices across the country will help to improve the
range and quality of our services. This synergistic partnership with Nova will
see the launch of SELENA+, and it will be deployed initially in 55 practices
across Malaysia through Rhazes' TeleOpto Platform, eventually expanding to the
other member practices within a year."
SELENA+ is capable of detecting up to 3
retinal diseases, principally diabetic retinopathy, glaucoma suspect and
age-related macular degeneration. Early screening and detection of these
diseases can significantly reduce vision loss, and in the case of diabetic
retinopathy, studies have shown that diabetes-related vision loss can be
reduced by up to 47 percent. EyRIS' SELENA+ has been approved for use by the
Malaysian Medical Device Authority since 22nd June 2020.
Aside from that,
there will also be an addition of a new algorithm to detect chronic kidney disease
("CKD") through the same fundus image used by EyRIS' SELENA+ to detect the 3
retinal diseases mentioned earlier.
Nova MSC's Group Chief Executive
Officer, Mr Lai Teik Kin added, "The addition of this new
algorithm will help us to be a gamechanger in the first stage diagnostic, a
drive towards being able to implement rapid screening tools to aid early
detection for systemic diseases. Our CKD algorithm boasts an 85 percent
accuracy rate, and uses of the non-invasive fundus imaging allows results to be
generated within 10-15 seconds with ease, speed and accuracy," Mr Lai
He also pointed
out that the recent gold award won by EyRIS at the Techblazer Awards 2021 in
the Most Promising Innovation category is a sign of the Group's push to bring
world-class technology into the world. The Techblazer Awards is Singapore's
highest accolade for technological innovation.
The push to
deploy SELENA+ into mainstream adoption in healthcare services has seen the
availability of its technology in 26 countries.
In order to
continue to expand the capabilities in disease detection through its
cutting-edge AI deep learning technology, EyRIS has inked a Research
Collaboration Agreement with a specialty centre under the National Healthcare
Group (NHG) to develop a new proprietary AI that detects melanoma using a
mobile phone camera. This was facilitated by NHG's Centre for Medical
Technologies and Innovations (CMTi).
Melanoma is the
deadliest form of skin cancer, and early detection is able to increase the
5-year survival rate to 99 percent. With 1 in every 3 cancer diagnoses being
skin cancer and the high melanoma incidence rate of 3.4 per 100,000 worldwide,
the ability to detect skin cancer early through non-invasive, mobile imaging
will contribute to the fight against skin cancer mortality.